Marc Beer – article recap

Marc became Founding CEO of ViaCell in April 2000. ViaCell was a biotechnology company. Its specialty was the preservation development and collection of umbilical cord blood stem cells. Over the next seven years, Marc lead the company to more than 300 employees. It went public in 2005 as (NASDAQ: VIAC), and in 2007 was acquired by PerkinElmer.

 

Erytech Pharma is a biopharmaceutical company that is publicly traded and Marc served on their board of directors at the same time he was CEO of ViaCell. Marc also held different positions with Genzyme. His most recent was as Vice President of Global Marketing. His duties included the responsibility for commercial launch of many different products focusing on the population of rare diseases globally.

 

In August 2016, Marc Beer, Ramon Iglesias, MD and Yolanda Lorie founded Renovia. Marc brought to the new start-up company over 25 years of commercialization and development experience. His experience included fields in biotechnology, diagnostics, pharmaceuticals and devices. Marc also held positions in pharmaceutical and diagnostic divisions of Abbott Laboratories and in marketing roles and sales.

 

Co-founded by Marc Beer, Renovia is a MedTech company based in Boston, Massachusetts. Marc Beer, has closed on a $32 million Series B round, and a $10 million venture debt, for Renovia Incorporation. These were accomplished in order to proceed with a few new products for pelvic floor disorders.

 

According to researchers, it is estimated that over 250 million women globally suffer from urinary incontinence, which is a pelvic floor disorder. Renovia is developing several therapeutic and diagnostic products to help with these disorders. The first product produced by Renovia Inc., for pelvic floor disorder was the Leva device. The Leva is a digital device that women can use at home. It was designed to help train and strengthen weakened pelvic floor muscles. The Leva device gained FDA approval in April 2018.

 

Renovia received funds from the investment firm Longwood Fund, who joined the Series B round. The Series B round was directed with the help of Perceptive Advisors, a New York based company, and Missouri-Based Ascension Ventures. The funds will be used for developing a new generation of the Leva device and the developing and testing of four more diagnostic and therapeutic products.

 

As CEO of Renovia, Beer is proud to be supported by these healthcare investment companies, who share the vision of Renovia. The vision is to make sure women are diagnosed and treated for the disease. Millions of women’s lives will be improved with the new products.

 

The groundbreaking diagnostic and therapeutic products developed by exclusive technologies, will produce a digital health program and give customers valuable information on treatment options for pelvic floor disorders. By educating women on the causes and cures, it will help to lower the health cost for women for years to come. Learn more : https://www.slideshare.net/MarcBeer